NASDAQ · SNTI

Senti Biosciences Holdings, Inc.

$0.37 -$0.03 (-7.48%) 1D After hours

Key Metrics

$12.58M
Market cap
1.27×
P/E · TTM
$16.00K
Revenue · TTM
$9.89M
Net income
EPS · TTM $0.99
Dividend yield
Free cash flow
Beta · 1Y 2.09
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    From its Apr 20 high, the share price fell 67%.

    Peak close $1.14 on Apr 20; trough close $0.37 on Jul 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -67%
  • Jul 16
    The stock moved -21.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 16
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 15
    The stock moved -39.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 15

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$12.58M
Enterprise value
Shares outstanding31.1M
52-wk range$0.36 – $2.88
Avg volume · 20D404.4K
Net cash
Book value / share$0.26
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Senti Biosciences Holdings, Inc.
IPO dateJun 9, 2022
Employees39

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E1.27
P/S786.02
P/FCF
EV/EBITDA
EV/Sales
Graham №$2.39

Profitability

Gross
Operating 73,631.3%
Net 61,818.8%
FCF
ROE / ROIC 70.1% · —

Financial Health

Current ratio1.04
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$522.00K

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

-12.0
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$2.39 vs $0.37
Trades below classic defensive value — Graham-cheap
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings